Supplementary insurance coverage for complementary health services (Yes) 202 55.0 Has a family physician (Yes) 308 83.5 Comorbid anxiety disorder ... professional of GAD in the past 12 months ...
US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...
Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...
Generalized anxiety disorder (GAD)--excessive or pathologic worry for at least 6 months--is a common psychiatric problem that is stable over time and distinguishable from other anxiety disorders.
PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry ...
Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback